The court agreed on a block for early generics of a widely prescribed MS treatment, finding even though a psoriasis medication had similar compounds, the drug’s exclusivity clock had not yet run out.

Biogen BIIB will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter ...

Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS ...